Predictive models for the practical management of renal cell carcinoma

Nature Reviews Urology

Volumn 9, Issue 2, 2012, Pages 73-84

  Lee, Lui Shiong ^a   Tan, Min Han ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; GIRENTUXIMAB; MOLECULAR MARKER; PAZOPANIB; SORAFENIB; SUNITINIB;

ALGORITHM; CANCER PATIENT; CANCER PROGNOSIS; CRYOTHERAPY; HIGH RISK PATIENT; HUMAN; KIDNEY CARCINOMA; KIDNEY SURGERY; METASTASIS; OUTCOME ASSESSMENT; PARTIAL NEPHRECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICAL MODEL; SYSTEMIC THERAPY;

CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS;

EID: 84857034562     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.224     Document Type: Review

References (118)

1. Chow, W.-H., Devesa, S. S., Warren, J. L. & Fraumeni, J. F. Rising incidence of renal cell cancer in the United States. JAMA 281, 1628-1631 (1999). (Pubitemid 29211773)
2. Sun, M. et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur. Urol. 59, 135-141 (2011).
3. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
4. Cheville, J. C., Lohse, C. M., Zincke, H., Weaver, A. L. & Blute, M. L. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Pathol. 27, 612-624 (2003). (Pubitemid 36514472)
5. Chen, Y. Y. & Uzzo, R. G. Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J. Natl Compr. Cancer Netw. 7, 635-643 (2009).
6. Heng, D. Y. et al. A unified prognostic model for first-and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): results from a large international study [abstract 4523]. J. Clin. Oncol. 28 (Suppl.), 15s (2010).
7. Heng, D. Y. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27, 5794-5799 (2009).
8. Manola, J. et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin. Cancer Res. 17, 5443-5450 (2011).
9. Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007). (Pubitemid 46849157)
10. Karakiewicz, P. I., Sun, M., Bellmunt, J., Sneller, V. & Escudier, B. Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria. Eur. Urol. 60, 48-56 (2011).
11. Motzer, R. et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 113, 1552-1558 (2008).
12. Motzer, R. J. et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol. 20, 2376-2381 (2002). (Pubitemid 34441667)
13. Karakiewicz, P. I. et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur. Urol. 55, 287-295 (2009).
14. Golimbu, M. et al. Renal cell carcinoma: survival and prognostic factors. Urology 27, 291-301 (1986). (Pubitemid 17050456)
15. Hollingsworth, J. M., Miller, D. C., Daignault, S. & Hollenbeck, B. K. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer 109, 1763-1768 (2007). (Pubitemid 46668538)
16. Sun, M. et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur. Urol. 60, 644-661 (2011).
17. Isbarn, H. & Karakiewicz, P. I. Predicting cancer-control outcomes in patients with renal cell carcinoma. Curr. Opin. Urol. 19, 247-257 (2009).
18. Karakiewicz, P. I. & Hutterer, G. C. Predicting cancer-control outcomes in patients with renal cell carcinoma. Curr. Opin. Urol. 17, 295-302 (2007). (Pubitemid 47344614)
19. Specht, M. C., Kattan, M. W., Gonen, M., Fey, J. & Van Zee, K. J. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann. Surg. Oncol. 12, 654-659 (2005). (Pubitemid 41126095)
20. Kattan, M. W. et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J. Clin. Oncol. 18, 3352-3359 (2000).
21. Karakiewicz, P. I. et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J. Urol. 176, 1354-1361 (2006).
22. Ghoneim, M. A. et al. A predictive model of survival after radical cystectomy for carcinoma of the bladder. BJU Int. 85, 811-816 (2000). (Pubitemid 30242783)
23. Mallett, S., Royston, P., Waters, R., Dutton, S. & Altman, D. G. Reporting performance of prognostic models in cancer: a review. BMC Med. 8, 21 (2010).
24. Altman, D. G. & Royston, P. What do we mean by validating a prognostic model? Stat. Med. 19, 453-473 (2000). (Pubitemid 30126878)
25. Janes, H., Pepe, M. S., Bossuyt, P. M. & Barlow, W. E. Measuring the performance of markers for guiding treatment decisions. Ann. Intern. Med. 154, 253-259 (2011).
26. Vickers, A. J. Prediction models in cancer care. CA Cancer J. Clin. http://dx.doi.org/10.3322/caac.20118.
27. Vickers, A. J., Cronin, A. M., Elkin, E. B. & Gonen, M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med. Inform Decis. Mak. 8, 53 (2008).
28. Vickers, A. J. & Elkin, E. B. Decision curve analysis: a novel method for evaluating prediction models. Med. Decis. Making 26, 565-574 (2006). (Pubitemid 44728772)
29. Kattan, M. W., Reuter, V., Motzer, R. J., Katz, J. & Russo, P. A postoperative prognostic nomogram for renal cell carcinoma. J. Urol. 166, 63-67 (2001). (Pubitemid 32565343)
30. Cindolo, L. et al. Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. Cancer 113, 65-71 (2008). (Pubitemid 351976387)
31. Zisman, A. et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 19, 1649-1657 (2001). (Pubitemid 32230864)
32. Sorbellini, M. et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J. Urol. 173, 48-51 (2005). (Pubitemid 39627669)
33. Ljungberg, B. et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol. 58, 398-406 (2010).
34. Parsons, J. K., Schoenberg, M. S. & Carter, H. B. Incidental renal tumors: casting doubt on the efficacy of early intervention. Urology 57, 1013-1015 (2001). (Pubitemid 32455557)
35. Campbell, S. C. et al. Guideline for management of the clinical T1 renal mass. J. Urol. 182, 1271-1279 (2009).
36. Frank, I. et al. Solid renal tumors: an analysis of pathological features related to tumor size. J. Urol. 170, 2217-2220 (2003). (Pubitemid 37413960)
37. Russo, P. et al. Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer 113, 84-96 (2008). (Pubitemid 351976390)
38. Kutikov, A., Egleston, B. L., Wong, Y. N. & Uzzo, R. G. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J. Clin. Oncol. 28, 311-317 (2010).
39. Lane, B. R. et al. Renal mass biopsy-a renaissance? J. Urol. 179, 20-27 (2008).
40. Jeldres, C. et al. Can renal mass biopsy assessment of tumor grade be safely substituted for by a predictive model? J. Urol. 182, 2585-2589 (2009).
41. Jewett, M. A. et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur. Urol. 60, 39-44 (2011).
42. Kutikov, A. et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur. Urol. 60, 241-248 (2011).
43. Lane, B. R. et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J. Urol. 178, 429-434 (2007). (Pubitemid 47030487)
44. Kunkle, D. A., Egleston, B. L. & Uzzo, R. G. Excise, ablate or observe: the small renal mass dilemma-a meta-analysis and review. J. Urol. 179, 1227-1233 (2008).
45. Beisland, C., Hjelle, K. M., Reisaeter, L. A. & Bostad, L. Observation should be considered as an alternative in management of renal masses in older and comorbid patients. Eur. Urol. 55, 1419-1427 (2009).
46. Levy, D. A., Slaton, J. W., Swanson, D. A. & Dinney, C. P. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J. Urol. 159, 1163-1167 (1998). (Pubitemid 28172785)
47. Lam, J. S. et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J. Urol. 174, 466-472 (2005). (Pubitemid 40981575)
48. Siddiqui, S. A. et al. Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol. BJU Int. 104, 778-785 (2009).
49. Breda, A., Konijeti, R. & Lam, J. S. Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection. Expert Rev. Anticancer Ther. 7, 847-862 (2007). (Pubitemid 47007991)
50. Chin, A. I., Lam, J. S., Figlin, R. A. & Belldegrun, A. S. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev. Urol. 8, 1-7 (2006).
51. Klatte, T., Lam, J. S., Shuch, B., Belldegrun, A. S. & Pantuk, A. J. Surveillance for renal cell carcinoma: why and how? When and how often? Urol. Oncol. 26, 550-554 (2008).
52. Medical Research Council Clinical Trials Unit. SORCE: a multi-centre phase III double-blind placebo-controlled study designed to examine the efficacy and tolerability of sorafenib (Nexavar) in patients with resected (total or partial) primary renal cell carcinoma (RCC) at high or intermediate risk of relapse [online], http://www.ctu.mrc.ac.uk/research-areas/study-details.aspx?s= 31 (2011).
53. Yap, T. A. & Eisen, T. Adjuvant therapy of renal cell carcinoma. Clin. Genitourin. Cancer 5, 120-130 (2006).
54. Leibovich, B. C. et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97, 1663-1671 (2003). (Pubitemid 36350710)
55. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct/show/NCT00326898?order=1 (2010).
56. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct/show/NCT00375674?order=4 (2011).
57. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00087022 (2011).
58. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01120249?term=NCT01120249&rank=1 (2011).
59. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01235962?term=NCT01235962&rank=1 (2011).
60. Tan, M. H. et al. Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma. Urology 75, 1365-1370 (2010).
61. Cindolo, L. et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 104, 1362-1371 (2005). (Pubitemid 41356151)
62. Liu, Z. et al. Validation of the current prognostic models for nonmetastatic renal cell carcinoma after nephrectomy in Chinese population: a 15-year single center experience. Int. J. Urol. 16, 268-273 (2009).
63. Yaycioglu, O. et al. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 58, 141-145 (2001). (Pubitemid 32728040)
64. Cindolo, L. et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int. 92, 901-905 (2003). (Pubitemid 37548262)
65. Zisman, A. et al. Mathematical model to predict individual survival for patients with renal cell carcinoma. J. Clin. Oncol. 20, 1368-1374 (2002). (Pubitemid 34177444)
66. Frank, I. et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 168, 2395-2400 (2002). (Pubitemid 35402623)
67. Karakiewicz, P. I. et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J. Clin. Oncol. 25, 1316-1322 (2007). (Pubitemid 46706877)
68. Tan, M. H. et al. The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma. Cancer 117, 5314-5324 (2011).
69. Wood, C. et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372, 145-154 (2008).
70. Motzer, R. J., Bander, N. H. & Nanus, D. M. Renal-cell carcinoma. N. Engl. J. Med. 335, 865-875 (1996).
71. Figlin, R. A. Renal cell carcinoma: management of advanced disease. J. Urol. 161, 381-386 (1999).
72. Motzer, R. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007). (Pubitemid 46089672)
73. Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007). (Pubitemid 46089673)
74. Sternberg, C. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase iii trial. J. Clin. Oncol. 28, 1061-1068 (2010).
75. Escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103-2111 (2007). (Pubitemid 350296300)
76. Hudes, G. R. et al. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin. Oncol. 36 (Suppl. 3), S26-S36 (2009).
77. Motzer, R. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456 (2008).
78. National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Kidney Cancer [online], http://www.nccn.org/professionals/physician-gls/f-guidelines.asp (2011).
79. Elson, P. J., Witte, R. S. & Trump, D. L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 48, 7310-7313 (1988). (Pubitemid 19014022)
80. de Forges, A. et al. Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis. Semin. Surg. Oncol. 4, 149-154 (1988).
81. Palmer, P. A. et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann. Oncol. 3, 475-480 (1992).
82. Fosså, S. D., Kramar, A. & Droz, J. P. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur. J. Cancer 30A, 1310-1314 (1994). (Pubitemid 24322068)
83. Motzer, R. J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530-2540 (1999). (Pubitemid 29368255)
84. Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P. & Mazumdar, M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289-296 (2002). (Pubitemid 34032623)
85. Mekhail, T. M. et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23, 832-841 (2005). (Pubitemid 46224183)
86. Choueiri, T. K. et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110, 543-550 (2007). (Pubitemid 47106142)
87. Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009).
88. Bracarda, S. et al. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-?2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU Int. 107, 214-219 (2011).
89. Escudier, B. et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 28, 2144-2150 (2010).
90. Motzer, R. J. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116, 4256-4265 (2010).
91. Rini, B. I. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378, 1931-1939 (2011).
92. Mickisch, G. H. et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358, 966-970 (2001). (Pubitemid 32913522)
93. Flanigan, R. C. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655-1659 (2001). (Pubitemid 33126820)
94. Abel, E. J. & Wood, C. G. Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat. Rev. Urol. 6, 375-383 (2009).
95. Choueiri, T. K. et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J. Urol. 185, 60-66 (2011).
96. Shuch, B. et al. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology-is up-front resection indicated and, if not, is it avoidable? J. Urol. 182, 2164-2171 (2009).
97. Culp, S. H. et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 116, 3378-3388 (2010).
98. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00930033?term=NCT00930033&rank=1 (2011).
99. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01099423?term=NCT01099423&rank=1 (2011).
100. Logan, T. et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features [abstract 5050]. J. Clin. Oncol. 26 (Suppl.) (2008).
101. Pierorazio, P. M. et al. Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int. 100, 755-759 (2007). (Pubitemid 47360194)
102. Barbastefano, J. et al. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int. 106, 1266-1269 (2010).
103. Vickers, A. J., Jang, K., Sargent, D., Lilja, H. & Kattan, M. W. Systematic review of statistical methods used in molecular marker studies in cancer. Cancer 112, 1862-1868 (2008). (Pubitemid 351536848)
104. Takahashi, M. et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc. Natl Acad. Sci. USA 98, 9754-9759 (2001). (Pubitemid 32769376)
105. Wuttig, D. et al. Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. Int. J. Cancer 125, 474-482 (2009).
106. Tan, M.-H. et al. Gene expression profiling of renal cell carcinoma. Clin. Cancer Res. 10 (Suppl.), 6315S-6321S (2004). (Pubitemid 39287485)
107. Brannon, A. R. et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 1, 152-163 (2010).
108. Zhao, H. et al. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med. 3, e13 (2006).
109. Kim, H. L. et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin. Cancer Res. 10, 5464-5471 (2004). (Pubitemid 39100484)
110. Parker, A. S. et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 115, 2092-2103 (2009).
111. Kirk, R. Risk factors. Oncotype DX assay predicts local recurrence in breast cancer. Nat. Rev. Clin. Oncol. 7, 300 (2010).
112. Webber, E. M., Lin, J. S. & Whitlock, E. P. Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction. PLoS Curr. 2, RRN1177 (2010).
113. Olivotto, I. A. et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J. Clin. Oncol. 23, 2716-2725 (2005). (Pubitemid 46179461)
114. Rini, B. I. et al. Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC) [abstract 4501]. J. Clin. Oncol. 28 (Suppl.), 15s (2010).
115. Zisman, A. et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol. 20, 4559-4566 (2002). (Pubitemid 35402959)
116. Raj, G. V. et al. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J. Urol. 179, 2146-2151 (2008).
117. Bamias, A. et al. Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. BMC Cancer 10, 45-57 (2010).
118. Escudier, B. et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J. Urol. 178, 1901-1905 (2007). (Pubitemid 47538612)